CTI supports Numab’s pipeline with CHF 895’000

The CTI supports Numab’s research on antibody-based approaches for the therapy of ion channel-driven health disorders with a grant of CHF 895’000. Numab is conducting the research activities within this project in collaboration with the Zürich University of applied Sciences (ZHAW).

 

David Urech, CSO, co-CEO and co-founder of Numab, commented: «With the assignment of this grant, the CTI acknowledges the potential of Numab’s technology for the discovery of ion-channel modulators. We are excited about this project, which may give raise to a break-through in antibody-based therapies». Oliver Middendorp, CBO, co-CEO and co-founder of Numab added:  «This grant is a great opportunity for Numab, since the project directly adds to Numab’s proprietary pipeline and thereby to corporate value».